107 Empagliflozin in heart failure with a preserved ejection fraction ≥50%: results from the emperor-preserved clinical trial | Heart

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Heart failure

107 Empagliflozin in heart failure with a preserved ejection fraction ≥50%: results from the emperor-preserved clinical trial

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Yousef Z

107 Empagliflozin in heart failure with a preserved ejection fraction ≥50%: results from the emperor-preserved clinical trial

Heart 2022;108:A79-A80.